<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02865863</url>
  </required_header>
  <id_info>
    <org_study_id>BIOT2600</org_study_id>
    <nct_id>NCT02865863</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effect of a Study Product on Quality of Life and Mood</brief_title>
  <official_title>Safety and Efficacy Profile of the Eurycomalongifoliawaterextract (Physta®)+Multivitamin Study Product</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KGK Synergize Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biotropics Malaysia Berhad</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>KGK Synergize Inc.</source>
  <brief_summary>
    <textblock>
      A phase II randomized, placebo controlled study evaluating the efficacy of
      Eurycomalongifoliawater extract (Physta®)+Multivitamin on quality of life and mood on 86
      healthy adults over a 24 week supplementation period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in quality of life after 24 weeks of supplementation with study product, measured using the SF-12 Quality of Life Questionnaire</measure>
    <time_frame>24 Week</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The change in mood after 24 weeks of supplementation with study product, measured using the POMS Questionnaire</measure>
    <time_frame>24 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change in stress after 24 weeks of supplementation with study product, measured using the Multi-Modal Stress Questionnaire</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in fasting AM Cortisol levels after 24 weeks of supplementation with study product.</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The change in CBC levels after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in CMP results after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in urinalysis results after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The number of adverse events reported after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in lipid panel results after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in total testosterone results after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The change in free testosterone results after 24 weeks of supplementation with study product</measure>
    <time_frame>24 weeks</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">86</enrollment>
  <condition>Quality of Life</condition>
  <condition>Mood</condition>
  <arm_group>
    <arm_group_label>Eurycomalongifoliawater extract (Physta®) +Multivitamin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Eurycomalongifoliawater extract (Physta®) +Multivitamin</intervention_name>
    <arm_group_label>Eurycomalongifoliawater extract (Physta®) +Multivitamin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy subjects ≥ 25 and ≤ 65 years of age.

          -  Body mass index (BMI) ≥ 18 and ≤30 kg/m2.

          -  Subjects must be employed in a job/position that has some degree of responsibility
             such that they experience a mid-level of stress at work.

          -  Subjects with a score of ≤ 18 in the Tension subscale and a score of ≤ 14 in the
             Fatigue subscale of the POMS Questionnaire.

          -  Judged by the Investigator to be in general good health on the basis of medical
             history.

          -  Females of child-bearing potential must agree to use appropriate birth control methods
             during the study.

          -  Understands the study procedures and signs forms providing informed consent to
             participate in the study and authorization for release of relevant protected health
             information to the study investigator

          -  Understands the study procedures and signs forms providing informed consent to
             participate in the study and authorization for release of relevant protected health
             information to the study investigator

        Exclusion Criteria:

          -  Subjects with any history of immune system disorder or auto-immune disorder including
             but not limited to the following:

             *AIDS, HIV, Ankylosing Spondylitis, Chronic Fatigue Syndrome, CREST syndrome, Crohn's
             disease, Dermatomyositis, Fibromyalgia, Grave's disease, Hashimoto's Thyroiditis,
             Lupus, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, PolyarteritisNodosa,
             Primary Biliary Cirrhosis, Psoriasis, Reynaud's Syndrome, Rhematoid Arthritis,
             Sarcoidosis, Scleroderma, Sjogren's Syndrome, Temporal Arthritis, Ulcerative Colitis,
             and Vitiligo

          -  Use of any immunosuppressive drugs in the last 12 months (including steroids or
             biologics)

          -  Any significant GI condition that would severely interfere with the evaluation of the
             study product including but not limited to inflammatory bowel disease (Ulcerative
             Colitis or Chron's), history of frequent diarrhea, history of surgery for weight loss
             (including gastric bypass or lapband), history of perforation of the stomach or
             intestines, gastroparesis, clinically important lactose intolerance

          -  Any active infection, or infection in the last month requiring antibiotics, antiviral
             medication, or hospitalization History or presence of cancer in the prior two years,
             except for non-melanoma skin cancer.

          -  Subjects with a history of seizure

          -  Recent history of (within 12 months) or strong potential for alcohol or substance
             abuse.

          -  Participation in a clinical study with exposure to any non-registered drug product
             within 30 days prior.

          -  Subject who are using herbal products containing androgenic/anxiolytic activity within
             30 days (one month washout is allowed)

          -  Individual has a condition the Investigator believes would interfere with his or her
             ability to provide informed consent, comply with the study protocol, which might
             confound the interpretation of the study results or put the person at undue risk.
             Including subjects who are Bed or wheelchair-bound

          -  Untreated or unstable Hypothyroidism

          -  Subjects with active eating disorder including anorexia nervosa, bulimia, and/or
             obsessive compulsive eating disorders

          -  Central Neurological disorders including but not limited to Spinal cord injuries,
             multiple sclerosis, Parkinson's disease

          -  Pregnant, lactating, planning to become pregnant or unwilling to use adequate
             contraception during the duration of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>TengkuShahrirTengku Adnan</last_name>
    <role>Study Director</role>
    <affiliation>Biotropics Malaysia Berhad</affiliation>
  </overall_official>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2016</study_first_submitted>
  <study_first_submitted_qc>August 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>August 12, 2016</last_update_submitted>
  <last_update_submitted_qc>August 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multivitamin</keyword>
  <keyword>Eurycomalongifoliawater extract</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Mood</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

